Pharmaxis Ltd (AU:SNT) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syntara Ltd has successfully raised A$15 million through a two-tranche placement, bolstering its cash reserves to approximately A$21.7 million. This capital will support various clinical trials and drug development initiatives, including those for myelofibrosis and Parkinson’s, as well as general operational expenses. The strong backing from institutional and high net worth investors reflects confidence in Syntara’s ongoing research and development programs.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.